跳到正文
BiopharmaTrend·· 2026-09-09AI 评分49

Insilico Medicine 研究:衰老生物标志物与时钟能否弥合长寿测量缺口?

The Measurement Challenge in Longevity: Can Aging Biomarkers and Clocks Close the Gap?

AI 导读

Insilico Medicine 团队在 Nature Biotechnology 报告,蛋白质组学衰老时钟显示 rentosertib 在特发性肺纤维化 Phase 2a 试验中与血清蛋白质组标志物预测的生物学年龄降低相关,但衰老时钟仍受数据噪声、验证标准缺失和因果关联不足限制。尽管已有数百种衰老时钟,这些因素仍限制其临床研究应用。相关试验正在验证并基准测试这些标志物,以推动其纳入监管框架。

正文 · 原文

  Business Intellilgence

An article published in Nature Biotechnology on 7 September 2026 by Alex Zhavoronkov’s team at Insilico Medicine and collaborators marks an important step forward for the field of drugs targeting aging. Using proteomics-based aging clocks, they showed that rentosertib, an anti-fibrotic that showed positive results in a Phase 2a trial in idiopathic pulmonary fibrosis, was associated with reductions in predicted biological age based on serum proteomic markers. This is not only a scientific milestone but also a methodological one, pointing the way for the use of aging clocks in trials of geroprotective medicines.

Aging Clocks

Targeting and measuring biological aging 

A growing number of longevity-focused biotech companies are testing interventions that aim to modify aging biology, from senolytics and immune-function enhancement to metabolic interventions, cellular reprogramming, and tissue engineering. Yet robust measurement of aging itself in humans remains a central bottleneck, complicating the testing of preventive and therapeutic strategies.

In the absence of a clear framework for measuring the process of aging beyond chronological age, most longevity drug development has focused on age-related proxy diseases. At the same time, a growing biomarker industry is trying to address this measurement gap. Academic groups and biotech companies are developing and validating markers linked to “biological age”, a concept intended to capture the physiological state of an organism, organ, tissue, or cell. Biological age can be distinct from an individual’s chronological age and differ for different organs and body systems. 

A particularly active field of aging biomarker research is that of so-called aging clocks. For such aging clocks biomarkers or biomarker profiles are translated into predictive biological age scores using computational models. While hundreds of aging clocks have been developed, noisy data, a lack of standardized validation, and missing causal links to aging biology currently still limit their use in clinical research and their value as interpretable, consumer-facing tools. However, trials that validate and benchmark these markers are underway to establish reliable aging biomarker profiles and support their integration into regulatory frameworks. Predictive biomarker profiles, whether expressed as aging clocks or in other formats, could become important tools for aging research, longitudinal monitoring and treatment-response assessment in clinical development, routine clinical monitoring, and consumer health tracking.

The drug-development bottleneck – why aging is hard to measure

To read the rest of this article, upgrade to a BiopharmaTrend Pro subscription.

Gain full access to all of our deep dives and content archives.

 Upgrade to Pro 

Insilico Medicine

来源:BiopharmaTrend · biopharmatrend.com